Zydus Lifesciences surges on getting final nod to market Amantadine extended-release capsules
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Zydus Lifesciences is currently trading at Rs. 1134.20, up by 20.35 points or 1.83% from its previous closing of Rs. 1113.85 on the BSE.
The scrip opened at Rs. 1147.05 and has touched a high and low of Rs. 1156.45 and Rs. 1128.05 respectively. So far 38036 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023.
Last one week high and low of the scrip stood at Rs. 1218.60 and Rs. 1105.30 respectively. The current market cap of the company is Rs. 112079.37 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.22% and 6.79% respectively.
Zydus Lifesciences (including its subsidiaries/ affiliates, hereafter referred to as Zydus) has received final approval from the United States Food and Drug Administration (USFDA) to market Amantadine extended-release capsules, 68.5 mg, and tentative approval for 137 mg (USRLD: Gocovri (amantadine) extended-release capsules, 68.5 mg and 137 mg).
Amantadine extended-release capsules are indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ - II, India.
This approval makes Zydus eligible for 180 days of exclusivity for Amantadine extended release capsules, 68.5 mg. The group now has 400 approvals and has so far filed over 465 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
